Continuous infusion versus intermittent infusion of vancomycin in critically ill patients undergoing continuous venovenous hemofiltration: a prospective interventional study

Table 3 The therapeutic efficacy and safety evaluation of vancomycin administrated in critically ill patients

Items	II group (n = 28)	CI group (n = 23)	Statistics	P
Targeted antimicrobial therapy, n (%)	16 (57.1)	18 (78.3)	2.534	0.111
Clinical success, n (%)	8 (50.0)	13 (72.2)	1.771	0.183
G⁺ bacterial eradication, n (%)	12 (75.0)	15 (83.3)	NA	0.681
Pesumed eradication	1 (8.3)	2 (13.3)	NA	> 0.999
Documented eradication	11 (91.7)	13 (86.7)	NA	> 0.999
Adverse reactions, n (%)
Leukopenia	0 (0.0)	1 (4.4)	NA	0.462
28-day mortality, n (%)	5 (17.9)	5 (21.7)	0.121	0.728

II group intermittent infusion group; CI group continuous infusion group; NA not applicable

ISSN: 1471-2334